LRRK2-IN-1, Menselijk, Gezuiverd Klein Molecule

Leucine-Rich Repeat Kinase 2 (LRRK2) is a member of the leucine-rich repeat kinase family. Mutations in the LRRK2 gene have been linked with late-onset autosomal dominant Parkinson's disease (PD) . A recent screening identified the analog LRRK2-IN-1 as a potent and selective inhibitor of LRRK2. This research by Deng et al (2011, Nat Chem Biol) showed that LRRK2-IN-1 suppressed LRRK2 kinase activity in vivo leading to dephosphorylation of Ser910/Ser935, loss of 14-3-3 binding and accumulation of LRRK2 within aggregrate fibrillar structures. LRRK2-IN-1, is the first selective and potent inhibitor of LRRK2. LRRK2-IN-1 inhibits both wild-type and G2019S mutant LRRK2 kinase activity with IC50 values of 13nM and 6nM respectively (Deng et al 2011, Nat Chem Biol) .

Leucine-rich repeat serine/threonine-protein kinase 2 (LRRK2-IN-1), human, purified small molecule, suitable to block.

Protein: Leucine-rich repeat serine/threonine-protein kinase 2; Dardarin; LRRK2; PARK8

Leucine-rich repeat serine/threonine-protein kinase 2 (LRRK2-IN-1)

Block

Purified

For research use only.

25°C (ambient)

Store dry, unopened vial protected from light for up to 3 months at RT or at -70°C for up to 1 year. Reconstitute product in 100% ACS grade DMSO and store at -80°C , in aliquots, protected from light, for up to 1 month. Prevent multiple freeze-thaw cycles. CAS Number 1234480-84-2.

>97% purified by HPLC

Dry, Synthetic chemical powder